Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC
Status:
Unknown status
Trial end date:
2019-03-30
Target enrollment:
Participant gender:
Summary
This study enrolls patients who have relapsed/advanced hepatocellular carcinoma (HCC, BCLC
stage C). The HCC tumor relapsed or metastasized through the body after standard treatment or
the patients cannot receive standard treatment under current conditions. This research study
uses specific HCC antigens CD8+ T cells, a new experimental treatment.
The purpose of this study is to evaluate the safety and tolerance as well as the potential
clinical efficacy of an adoptive transfer of CD8+ T cells, sorted with human leukocyte
antigen (HLA)-peptide multimers and specific for Glypican (GPC)-3 /New York Esophageal
Squamous-1 (NY-ESO-1) /alpha-fetoprotein (AFP) antigens and cultured in vitro, to patients
suffering from relapsed/advanced hepatocellular carcinoma (HCC).